Taken together, these findings suggest that oHSV-1 treatment induced tumor rejection by eliciting an effective antitumoral immune response characterized by a significative recruitment of both CD4 + and CD8 + T cells, capable of protecting mice from subsequent tumor challenges. This evidence concerns the gene CD4 and neoplasm.